参考文献/References:
[1]Gangat N,Patnaik MM,Tefferi A.Myelodysplastic syndromes: Contemporary review and how we treat[J].Am J Hematol,2016,91(1):76-89. [2]Jabbour E,Short NJ,Montalban-Bravo G,et al.Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN[J].Blood,2017,130(13):1514-1522. [3]Wu L,Song L,Xu L,et al.Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes[J].Tumour Biol,2016,37(4):4633-4640.[4]Migdady Y,Barnard J,AlAli N,et al.Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis[J].Clin Lymphoma Myeloma Leuk,2018,18(8):528-532. [5]Rujirachaivej P,Siriboonpiputtana T,Rerkamnuaychoke B,et al.The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome[J].Asian Pac J Cancer Prev,2018,19(7):1825-1831.[6]Song J,Hussaini M,Qin D,et al.Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance[J].Am J Clin Pathol,2020,154(1):48-56. [7]Tang Y,Miao M,Han S,et al.Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes:A meta-analysis[J].Crit Rev Oncol Hematol,2019(133):74-83.[8]Jafari PA,Sadeghian MH,Miri HH,et al.Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis[J].Crit Rev Oncol Hematol,2020(145):102832. [9]Guo Z,Zhang SK,Zou Z,et al.Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis[J].Leuk Res,2017(58):102-107. [10]Nagata Y,Ogawa S.A novel prognostic model incorporating genetic profiling for myelodysplastic syndromes[J].Rinsho Ketsueki,2017,58(7):776-786. [11]Wang R,Gao X,Yu L.The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis[J].BMC Cancer,2019,19(1):389.[12]Donehower LA,Soussi T,Korkut A,et al.Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas[J].Cell Rep,2019,28(5):1370-1384.[13]Stengel A,Kern W,Haferlach T,et al.The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases[J].Leukemia,2017,31(3):705-711.[14]Bernard E,Nannya Y,Hasserjian RP,et al.Implications of TP53 Allelic Stat for Genome Stability,ClinicalPresentation and Outcomes in Myelodysplastic Syndrome[J].Bio Rxiv,2019,86(5):674-688.[15]Sallman DA,Komrokji R,Vaupel C,et al.Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes[J].Leukemia,2016,30(3):666-673. [16]Belickova M,Vesela J,Jonasova A,et al.TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes[J].Oncotarget,2016,7(24):36266-36279. [17]Montalban-Bravo G,Kanagal-Shamanna R,Benton CB,et al.Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes[J].Blood Adv,2020,4(3):482-495. [18]Pellagatti A,Armstrong RN,Steeples V,et al.Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations[J].Blood,2018,132(12):1225-1240. [19]Nguyen L,Zhang X,Roberts E,et al.Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1[J].Leuk Lymphoma,2020,61(6):1395-1405.[20]Hamilton BK,Rybicki L,Hirsch C,et al.Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes[J].Bone Marrow Transplant,2019,54(8):1281-1286.[21]Todisco G,Creignou M,Gallì A,et al.Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms[J].Leukemia,2021,35(8):2371-2381.[22]Lin Y,Zheng Y,Wang ZC,et al.Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis[J].Hematology,2016,21(8):454-461. [23]Khan M,Cortes J,Kadia T,et al.Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia[J].Int J Mol Sci,2017,18(8):1618. [24]Xu F,Wu LY,He Q,et al.Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes[J].Sci Rep,2017(7):43113. [25]Vikas M,Jia L,Siqin Z,et al.Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes[J].American Journal of Hematology,2020,95(2):133-143. [26]Arbab JP,Ayatollahi H,Sadeghi R,et al.Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis[J].Hematology,2018,23(10):778-784. [27]Yimpak P,Tantiworawit A,Rattanathammethee T,et al.Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand[J].Asian Pac J Cancer Prev,2019,20(4):1215-1221. [28]Zhang ZM,Lu R,Wang P,et al.Structural basis for DNMT3A-mediated de novo DNA methylation[J].Nature,2018,554(7692):387-391. [29]Sasaki K,Kanagal-Shamanna R,Montalban-Bravo G,et al.Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia[J].Cancer,2020,126(4):765-774.[30]Park DJ,Kwon A,Cho BS,et al.Characteristics of DNMT3A mutations in acute myeloid leukemia[J].Blood Res,2020,55(1):17-26. [31]Lin ME,Hou HA,Tsai CH,et al.Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome[J].Clin Epigenetics,2018(10):42. [32]Liang S,Zhou X,Pan H,et al.Prognostic value of DNMT3A mutations in myelodysplastic syndromes: ameta-analysis[J].Hematology,2019,24(1):613-622. [33]Kuendgen A,Müller-Thomas C,et al.Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature[J].Oncotarget,2018,9(45):27882-27894.[34]Song J,Hussaini M,Qin D,et al.Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance[J].Am J Clin Pathol,2020,154(1):48-56.[35]Martín I,Such E,Navarro B,et al.Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS) [J].Leuk Lymphoma,2017,58(7):1686-1693. [36]Zhang J,Zhao H,Wu K,et al.Knockdown of spliceosome U2AF1 significantly inhibits the development of human erythroid cells[J].J Cell Mol Med,2019,23(8):5076-5086. [37]Kim SY,Kim K,Hwang B,et al.The high frequency of the U2AF1 S34Y mutation and its association with isolated trisomy 8 in myelodysplastic syndrome in Asians, butnot in Caucasians[J].Leuk Res,2017,61(2):96-103. [38]Jung SH,Kim YJ,Yim SH,et al.Somatic mutations predic-t outcomes of hypomethylating therapy in patients with myelodysplastic syndrome[J].Oncotarget,2016,7(34):55264-55275.[39]Li B,Zou D,Yang S,et al.Prognostic significance of U2AF1 mutations in myelodysplastic syndromes: a meta-analysis[J].J Int Med Res,2020,48(3):300060519891013. [40]Wang H,Guo Y,Dong Z,et al.Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome[J].Sci Rep,2020,10(1):22-186. [41]Jung HA,Jung CW,Jang JH.Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome[J].Korean J Intern Med,2021,36(2):413-423. [42]陈园园,石锐,郭素青,等.地西他滨治疗伴DNA甲基转移酶基因突变的骨髓增生异常综合征患者的疗效分析[J].中国实验血液学杂志,2020,28(4):1292-1297.[43]Du MY,Xu M,Deng J,et al.Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population[J].J Cancer,2020,11(2):508-519.[44]Yun J,Ji YS,Jang GH,et al.TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy[J].Curr Issues Mol Biol,2021,43(2):917-931. [45]Cedena MT,Rapado I,Santos-Lozano A,et al.Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes[J].Oncotarget,2017,8(63):106948-106961. [46]Zhao WS,Zhang YT,Jiang QL,et al.Correlation between U2AF1 Gene Mutation Characteristics and Clinical Manifestations and Prognosis in Patients with Myelodysplastic Syndrome[J].Journal of Experimental Hematology,2020,28(6):1977-1984.[47]Hong JY,Seo JY,Kim SH,et al.Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome[J].Anticancer Res,2015,35(5):3081-3089.[48]Cai L,Zhao X,Ai L,et al.Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis[J].Clin Exp Med,2020,20(3):361-371.[49]Bao ZH,Zhao HG,Yu HE.Clinical Efficacy and Prognostic Factors of Decitabine for Treatment of Myelodysplastic Syndrome[J].Journal of Experimental Hematology,2018,26(6):1702-1707.[50]Fang K,Qi J,Zhou M,et al.Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in MyelodysplasticSyndromes.Clin Lymphoma Myeloma Leuk[J].Clin Lymphoma Myeloma Leuk,2021(25):S2152-2650(21)02043-7.[51]Idossa D,Lasho TL,Finke CM,et al.Mutations and karyotype predict treatment response in myelodysplastic syndromes[J].Am J Hematol,2018,93(11):1420-1426.[52]Yoshizato T,Nannya Y,Atsuta Y,et al.Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation[J].Blood,2017,129(17):2347-2358. [53]Heuser M,Gabdoulline R,L?ffeld P,et al.Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation[J].Ann Hematol,2017,96(8):1361-1372. [54]Kr?觟ger N.Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes[J].Semin Hematol,2017,54(3):154-158.[55]Lindsley RC,Saber W,Mar BG,et al.Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation[J].N Engl J Med,2017,376(6):536-547.